Phase 3 results on new CLL treatment presented at EHA Conference

1 sourceFirst reported 1 month agoUpdated 1 month ago

AI summary: catch up in 20 seconds

AbbVie announced Phase 3 results for a new combinational therapy for CLL.
The study showed the long-term safety and efficacy of venetoclax for untreated patients.
Data demonstrates prolonged time until next treatment, enhancing patient care.
The combination has shown positive responses compared to other treatment regimens.

Generated by AI from the 1 sources below · always verify with the originals

AI summary: catch up in 20 seconds

Summarising the coverage…

Generated by AI from the 1 sources below · always verify with the originals

All coverage (1)

Συνέδριο Ευρωπαϊκής Αιματολογικής Εταιρείας: Τα αποτελέσματα της φάσης 3 για νέο συνδυαστικό σχήμα για την χρόνια λεμφοκυτταρική λευχαιμίαiefimerida.gr · 1 month ago

No comments yet. Be the first to join the discussion.

AI summary: catch up in 20 seconds

AbbVie announced Phase 3 results for a new combinational therapy for CLL.
The study showed the long-term safety and efficacy of venetoclax for untreated patients.
Data demonstrates prolonged time until next treatment, enhancing patient care.
The combination has shown positive responses compared to other treatment regimens.

Generated by AI from the 1 sources below · always verify with the originals